Form 4: CalciMedica CEO Acquires Shares in Private Placement

CalciMedica CEO Rachel Leheny acquired 186,729 shares of common stock in a private placement transaction on June 25, 2026.

Summary

• Rachel Leheny, CEO of CalciMedica, Inc. (CALC), acquired 186,729 shares of common stock on June 25, 2026.
• The acquisition was made through a Securities Purchase Agreement dated June 23, 2026, with a closing on June 25, 2026.
• The transaction was approved by an independent committee of the Issuer's Board of Directors.
• Following the transaction, Leheny directly beneficially owns 317,655 shares.
• Additionally, Leheny indirectly beneficially owns shares through the Scheibler-Leheny Family Living Trust (3,500 shares), her Spouse (1,000 shares), Valence Investments SPV IV, LLC (356,989 shares), Valence Investments SPV V, LLC (66,228 shares), and Valence Investments SPV VI, LLC (316,109 shares).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The CEO's purchase of shares is a positive signal of confidence, and the independent committee approval is a good governance indicator. However, the lack of detailed financial performance and the nature of indirect ownership introduce some ambiguity.

Positives

• CEO's direct acquisition of company stock can signal confidence in the company's future prospects.
• The transaction was approved by an independent committee, suggesting adherence to good corporate governance practices.
• The CEO's beneficial ownership, both direct and indirect, remains substantial, indicating continued significant investment.

Negatives

• The filing does not provide the price at which the shares were acquired, only the amount of securities acquired and the price per share for the transaction (0.8033).
• The filing details a significant number of indirect beneficial ownerships through various LLCs, which can sometimes obscure the ultimate control and pecuniary interest.

Risks

• The nature of the Securities Purchase Agreement and the specific terms under which the shares were acquired are not fully detailed, which could represent a risk if unfavorable terms were involved.
• The disclaimer of beneficial ownership for the Valence Securities, except to the extent of her pecuniary interest, introduces a degree of uncertainty regarding her actual control over those shares.

Future Outlook

The filing itself is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Management Comments

• The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026.
• The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
• The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities").
• The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider stock purchases, particularly by a CEO, are often viewed positively by the market as they can indicate management's belief in the company's intrinsic value and future growth prospects. This transaction, occurring in a private placement, suggests a capital-raising activity that was approved by an independent board committee, which is a positive governance signal.

Corporate Governance

Related Party Transactions

• The acquisition of 186,729 shares by CEO Rachel Leheny from the Issuer on June 25, 2026, is a related party transaction as she is an officer and director of the company.

Stakeholder Impact

• Shareholders: The CEO's purchase may be interpreted as a positive signal of confidence, potentially influencing investor sentiment. The capital raised through the purchase could also support the company's operations or growth initiatives.
• Management: Reinforces the CEO's commitment to the company through direct and indirect share ownership.
• Creditors: The capital raised could strengthen the company's financial position, potentially benefiting creditors.

Next Steps

• Monitor future filings for any further changes in beneficial ownership by Rachel Leheny or other insiders.
• Observe the company's subsequent financial performance and strategic developments to assess the impact of this transaction and the company's overall trajectory.

Key Dates

Recommendation

The filing reports an insider purchase by the CEO, which is generally a positive signal. However, it is a Form 4 detailing a specific transaction and does not provide comprehensive financial results or strategic updates that would warrant a stronger recommendation. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor further developments.

Keywords

CalciMedica, CALC, Form 4, SEC Filing, Insider Trading, Stock Acquisition, Securities Purchase Agreement, Beneficial Ownership, Rachel Leheny, CEO, Private Placement